Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD
Lutein with or without zeaxanthin showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (low certainty).
1 finding from 1 review
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD
Vitamin E showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (low certainty).
1 finding from 1 review
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD
Zinc showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (moderate certainty).
1 finding from 1 review
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD
Antioxidant multivitamin and mineral supplement probably leads to lower progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · type 1 or type 2 diabetics
It is very uncertain whether blood pressure intervention/intensive blood pressure intervention changes visual acuity (loss of 3 lines or more) by 5 years compared with placebo/standard blood pressure intervention (very low certainty).
1 finding from 1 review
Progression to visual loss (loss of 3 or more lines on logMAR chart) · proliferative diabetic retinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of a reduction in visual acuity of 10 ETDR letters or more · people with type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants with 1 or more recurrent APAC episodes in the same eye (lower number of events is better) · Participants with acute primary angle closure after initial medical treatment to lower intraocular pressure
It is very uncertain whether phacoemulsification changes proportion of participants with 1 or more recurrent APAC episodes in… compared with laser peripheral iridotomy (very low certainty).
1 finding from 1 review
Visual improvement at end of treatment, as defined by two or more Snellen lines · participants with acute CME (< 4 months) following cataract surgery
It is very uncertain whether NSAID changes visual improvement at end of treatment, as defined by two or more… compared with placebo or active control (very low certainty).
1 finding from 1 review
Visual improvement at end of treatment, as defined by two or more Snellen lines · participants with acute or chronic CME following cataract surgery
It is very uncertain whether NSAID changes visual improvement at end of treatment, as defined by two or more… compared with active control (very low certainty).
1 finding from 1 review
Visual improvement at end of treatment, as defined by two or more Snellen lines · participants with chronic CME (≥ 4 months) following cataract surgery
It is very uncertain whether NSAID changes visual improvement at end of treatment, as defined by two or more… compared with placebo (very low certainty).
1 finding from 1 review
CAS improvement (decrease) by 2 or more points · thyroid‐associated ophthalmopathy
Summary of findings table ‐ Rituximab showed no clear difference in CAS improvement (decrease) by 2 or more points compared with intravenous methylprednisolone (low certainty).
1 finding from 1 review
Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with placebo (very low certainty).
1 finding from 1 review
NOSPECS improvement (decrease) by 2 classes or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes NOSPECS improvement (decrease) by 2 or more classes compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Palpebral aperture improvement (decrease) by 3 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes palpebral aperture improvement (decrease) by 3 mm or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Motility improvement (increase) by 1 class or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes motility improvement (increase) by 1 class or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
CAS improvement (decrease) by 2 or more points · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes CAS improvement (decrease) by 2 or more points compared with placebo (very low certainty).
1 finding from 1 review
NOSPECS improvement (decrease) by 2 classes or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes NOSPECS improvement (decrease) by 2 classes or more compared with placebo (very low certainty).
1 finding from 1 review
Measurable change in stereopsis after 8 (± 2) weeks and 16 (± 2) weeks of intervention 'Real change' in stereopsis is defined as a change in stereoacuity of two or more octaves. · 5‐ to 8‐year‐old children with amblyopia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found